The partnership between GSK CureVac that was formed during the pandemic is now restructured into a deal valued at up to €1,45 billion. The FTSE 100 drug company has acquired
The partnership between GSK CureVac that was formed during the pandemic is now restructured into a deal valued at up to €1,45 billion. The FTSE 100 drug company has acquired






